SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending following a double-beat earnings report that failed to satisfy investors, leading to a sharp price decline as concerns over slowing growth in China and the impact of tariffs intensify. The community is deeply divided, with many long-term shareholders expressing frustration over the brand's perceived loss of relevance and management's strategy, while others view the current price level as a potential bottom-fishing opportunity.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors await the final 10-K filing and Q4 earnings report, closely monitoring the company's debt reduction progress and the appreciation of major holdings like BW and Applied Digital. The community is actively debating the stock's potential for a valuation re-rating, with bulls highlighting the cleanup of debt obligations and significant short interest as catalysts for a potential squeeze.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is facing intense scrutiny as investors weigh its aggressive international expansion and margin-compressing investment cycles against a structurally weak housing market. While the community remains deeply divided between those betting on a potential short squeeze and those fearing a long-term cash sink due to ongoing execution risks and tariff exposure.

THE FAMOUS DOG JUMPING INTO THE WATER FROM TIKTOK WITH 500M+ VIEWS.  A few facts about me - Signature Pool Dive - Serial Killer - Silly  Roadmap 1. BORN - Launch of a token, development of a family of holders and a twitter 2.BORN - Project development, marketing and connect KOLs 3. CEX listings - Listing on top exchanges and partnerships  Being a memecoin doesn’t mean we won’t have utilities. Our developers will develop some fun and useful tools for its community members as we continue to BUIDL! Our main goal is to make sure everyone has access to our utilities, so we build it with scalability in mind.  Ready to Splash?

Splash Dog

Community interest in $BUSTER is surging as traders highlight its building momentum and potential within the Solana ecosystem. Investors are actively discussing the token's structural development and early-stage entry points, viewing the recent price action as a sign of gathering strength.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently garnering significant attention as traders navigate high volatility, with the community actively debating its role as a high-speed settlement rail compared to Ethereum and discussing the surge of new meme coin projects within its ecosystem. Despite broader market concerns, bullish sentiment persists among long-term holders who are focusing on network developer momentum, institutional adoption, and the potential for rapid recovery driven by retail interest.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors monitor the company's early commercial rollout of Yartemlea following recent FDA approval, with the community actively debating potential revenue ramps and milestone payments from the partnership with Novo Nordisk. Discussion centers on the stock's significant pullback from post-approval highs, with many investors maintaining a bullish stance due to the asset's orphan drug status, lack of competition, and the anticipation of forthcoming quarterly earnings reports.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG is generating significant buzz as its dedicated community actively promotes the project across social platforms with persistent engagement and calls to action. The community emphasizes the token's longevity in the space and its ongoing efforts to build momentum while frequently interacting with other popular crypto assets.

Tema ETF Trust - Tema Space Innovators ETF

Investors are gaining exposure to the broader space economy through this newly listed ETF, with community discussions centering on its strategic holdings in key industry players and comparisons to other space-focused stocks.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The QQQ is rallying sharply as markets react to unconfirmed reports and optimistic commentary from leadership regarding a potential off-ramp in the Iran conflict. While traders are fueling the upside on hopes of de-escalation, the community remains deeply divided, with many debating whether this is a genuine shift or a 'dead cat bounce' driven by short covering and month-end window dressing amidst persistent geopolitical uncertainty.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is surging following a strategic collaboration with Pfizer involving the clinical development of ORIC-533, coupled with a private placement that provided fresh capital. Investors are actively debating the stock's potential for a short squeeze, citing strong institutional support and the credibility of a Big Pharma partnership as catalysts that may drive further upward momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$COGT  
 
Cogent announces additional results from SUMMIT trial of bezuclastinib 
 
Cogent Biosciences announced additional clinical results from the SUMMIT trial with bezuclastinib in patients with NonAdvanced Systemic Mastocytosis at the American Academy of Allergy Asthma &amp; Immunology, AAAAI, Annual Meeting. As previously reported, bezuclastinib demonstrated clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints. Treatment with bezuclastinib resulted in rapid, durable, statistically significant symptomatic improvements which continued to deepen out to 48 weeks: Patients on bezuclastinib reported a -32.0 point mean change in TSS, representing a 56% relative improvement in TSS from baseline; 86% of patients achieved a clinically meaningful threshold of 30% improvement in symptoms; 99% of patients had at least 50% reduction in serum tryptase, with 83.3% of patients achieving normalization.  
 
Bezuclastinib demonstrates strong evidence of disease modification in NonAdvSM patients based on: Significant correlation shown between serum tryptase reduction and symptomatic improvement as measured by TSS, all symptom domains, and 10/11 individual symptoms; Clinically meaningful improvements in bone mineral density at week 24 for patients treated with bezuclastinib, regardless of baseline bone health severity; 50% of patients reported a dose reduction and/or discontinuation of best supportive care medicines during the treatment period at week 48.

Randy

Claudiu Simon Ciobanu

Devis

StockTwits Web

Cogent Biosciences Inc

  
 
Cogent announces additional results from SUMMIT trial of bezuclastinib 
 
Cogent Biosciences announced additional clinical results from the SUMMIT trial with bezuclastinib in patients with NonAdvanced Systemic Mastocytosis at the American Academy of Allergy Asthma & Immunology, AAAAI, Annual Meeting. As previously reported, bezuclastinib demonstrated clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints. Treatment with bezuclastinib resulted in rapid, durable, statistically significant symptomatic improvements which continued to deepen out to 48 weeks: Patients on bezuclastinib reported a -32.0 point mean change in TSS, representing a 56% relative improvement in TSS from baseline; 86% of patients achieved a clinically meaningful threshold of 30% improvement in symptoms; 99% of patients had at least 50% reduction in serum tryptase, with 83.3% of patients achieving normalization.  
 
Bezuclastinib demonstrates strong evidence of disease modification in NonAdvSM patients based on: Significant correlation shown between serum tryptase reduction and symptomatic improvement as measured by TSS, all symptom domains, and 10/11 individual symptoms; Clinically meaningful improvements in bone mineral density at week 24 for patients treated with bezuclastinib, regardless of baseline bone health severity; 50% of patients reported a dose reduction and/or discontinuation of best supportive care medicines during the treatment period at week 48.

Microsoft Corp

iShares Russell 2000 ETF

iShares 20+ Year Treasury Bond ETF

Alphabet Inc Class A

DonCorleone77

@DonCorleone77 my man! Ur here too. Always happy when i come along one of ur posts in the wild. Keep on keep on

StockTwits For Android 

 my man! Ur here too. Always happy when i come along one of ur posts in the wild. Keep on keep on